A Phase 2 Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer


Full Title

Combination targeted and Hormonal treAtMEnt of Low-gradE serous Ovarian cancer in the upfroNt setting (CHAMELEON)


Researchers want to see how well a new combination of drugs works to treat low-grade serous ovarian cancer. The drugs are avutometinib, defactinib, and letrozole. The people in this study have ovarian cancer that cannot be completely removed with surgery.

Avutometinib and defactinib work against cancer by blocking a protein (the kinase protein) that plays a role in cancer growth. Letrozole blocks the body from producing estrogen, a hormone that can cause cancer growth. All three medications are taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have low-grade serous ovarian cancer.
  • Have cancer that was not able to be completely removed with surgery, or you are not yet eligible for surgery.
  • Have not received any prior chemotherapy or hormonal therapy for low-grade serous ovarian cancer.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. Rachel Grisham’s office at 646-888-4653.




Phase II (phase 2)

Disease Status

Newly Diagnosed & Relapsed/Refractory



ClinicalTrials.gov ID